YAbS







Bapineuzumab Terminated Naked monospecific

Antibody Information

Entry ID 1754
INN Bapineuzumab
Status Terminated
Drug code(s) AAB-001
Brand name None
mAb sequence source mAb humanized
General Molecular Category Naked monospecific
Format, general category Full length Ab
Format details None
Isotype (Fc) IgG1
Light chain isotype kappa
Linker None
Ave. DAR None
Conjugated/fused moiety None
Discovery method/technology None

Therapeutic information

Target(s) Amyloid beta (N-terminal)
Indications of clinical studies Alzheimer's disease
Primary therapeutic area Neurological disorders

Development stage information

Phase lengths*
*The graph represents early-stage clinical development phase lengths. For molecules approved or under evaluation for marketing authorization in the US is provided a complete overview of all clinical development phase lengths. Phase lengths are calculated from the start of the first in human (FIH) study (Start of clinical phase). “Start of Phase 2” bar represents Phase 1 length (Start of clinical phase to start of Phase 2); “Start of Phase 3” bar represents Phase 1+2 length (Start of clinical phase to start of Phase 3); “Date BLA/NDA submitted” bar represents Phase 1+2+3 length (Start of clinical phase to Date BLA/NDA submitted); and “Date of first US approval” bar represents Phase 1 to first US approval length (Start of clinical phase to Date of first US approval).
Most advanced stage of development (global) Terminated at Phase 3
Status Inactive
Start of clinical phase (IND filing or first Phase 1) February 15, 2004
Start of Phase 2 April 15, 2005
Start of Phase 3 December 15, 2007
Date BLA/NDA submitted to FDA
Year of first approval (global) None
Date of first US approval
INN, US product name None
US or EU approved indications None

Company information

Company Pfizer
Licensee/Partner None
Comments about company or candidate Fast track. Developed by Wyeth
Full address of company 66 Hudson Boulevard East, New York, NY 10001-2192 USA
North America
United States of America
https://www.pfizer.com/contact

Description/comment

Target is Amyloid beta N-terminal as per https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4772335/

Additional information

Anticipated events None
Factor(s) contributing to discontinuation None